Evidence map›Paper›PMID 32028958›Full record

ArticleWorld journal of surgical oncology2020

Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.

Jiayu Zhang, Yue Wang, Tiancheng Zhao, Yezhou Li, Leilei Tian, Jinming Zhao, Jingxin Zhang

Open access · goldAbstract readEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Jiayu ZhangDepartment of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Yue WangDepartment of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, China.
Tiancheng ZhaoDepartment of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, China. zhaotiancheng@jlu.edu.cn.
Yezhou LiDepartment of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Leilei TianOperating Room, China-Japan Union Hospital of Jilin University, Changchun, China.
Jinming ZhaoDepartment of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Jingxin ZhangDepartment of General Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Jilin University · CNUnion Hospital · CNAffiliated Hospital of Jiangsu University · CNJiangsu University · CNThe Fifth People’s Hospital of Suzhou · CN

Funding

The crosswise project of Jilin University 2019YX022
6 · The paper itself

Abstract

backgroundPancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis that lacks specific diagnostic markers. Mucin 5AC (MUC5AC) is a member of the mucin family, a heterogeneous group of high molecular weight, heavily glycosylated proteins that could be either membrane-bound or secreted. This multi-central study is to evaluate the performance of serum MUC5AC in combination with carbohydrate antigen 19-9 (CA19-9) for the diagnosis of PC in Asian.

methodsSixty-one patients with PC (comprised of early pancreatic cancer [n = 30] and late pancreatic cancer [n = 31] patients), 29 benign control, 35 choledocholithiasis, 25 chronic pancreatitis, and 34 healthy controls, were recruited from two hospitals. Serum levels of MUC5AC were evaluated by commercial ELISA kits. CA19-9 was measured by chemiluminescence immunoassay. The cutoff value of MUC5AC was determined based on optimal sensitivity and specificity.

resultsSerum MUC5AC in patients with PC (210.1 [100.5-423.8] ng/mL) presented higher levels than those in controls. The combined biomarker panel (MUC5AC and CA19-9) presented better performance and improved specificity to differentiate PC from controls (AUC 0.894; 95% CI (0.844-0.943), sensitivity 0.738, specificity 0.886) than CA19-9 (p = 0.043) or MUC5AC alone (p = 0.010); however, the latter two had no difference (p = 0.824).

conclusionsSerum MUC5AC is a potential biomarker for PC. The combination with CA19-9 presents improved specificity and better performance.

Indexed as

AdenocarcinomaArea Under CurveBiomarkers, TumorCA-19-9 AntigenCase-Control StudiesDiagnosis, DifferentialFemaleFollow-Up StudiesHumansMaleMiddle AgedMucin 5ACPancreatic NeoplasmsPrognosisBiomarkers, TumorCA-19-9 AntigenMUC5AC protein, humanMucin 5ACBiomarkerCarbohydrate antigen 19-9 (CA19-9)Mucin 5AC (MUC5AC)Pancreatic cancer (PC)

Identifiers

PMID32028958
PMCPMC7006398
OpenAlexW3010491889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.